| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.6 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | -0.099 | 0.6 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |